ClearPoint Neuro, Inc.

Total revenue was $10.9 million in Q2 2026, up from $9.2 million in Q2 2025, for 18% growth year over year. Biologics and drug delivery revenue declined 15% to $4.0 million from $4.7 million, neurosurgery navigation revenue increased to $5.6 million, and capital equipment/software revenue rose 24% to $1.3 million. Gross margin was 62%, up 2 percentage points from 60% in the prior-year quarter. R&D expense was $4.6 million, sales and marketing was $6.8 million, and G&A was $5.6 million. Cash and cash equivalents were $29.4 million at June 30, 2026 versus $45.9 million at December 31, 2025, with $15 million of operational cash burn through Q2 and $2 million of tax-related payments. Management raised 2026 revenue guidance to $48 million to $52 million and said the second half should see a lower operational cash burn as IRRAS integration is completed. Joe Burnett also said 2027 total growth could be in the high teens to about 20%, with upside from CAL ramp and possible commercial approvals.

Joe Burnett framed the quarter as a turning point, saying the company is reprioritizing around three areas: commercial readiness for faster-moving biopharma programs, ramping the CAL preclinical facility, and advancing focused ultrasound plus robotics/Harmony software. His tone was upbeat and strategic, with repeated emphasis that recent FDA and partner developments could bring commercial launches sooner than previously expected. He said the company wants to be an essential partner in neuro drug delivery, especially for cell and gene therapies, and described the second half of 2026 as the key investment period.

Danilo D’Alessandro reported Q2 revenue of $10.9 million, up 18% year over year, with gross margin at 62% versus 60% last year. He broke out revenue strength in neurosurgery navigation and capital equipment/software, while noting the biologics and drug delivery decline was mainly due to a prior-year single customer order that did not recur. He also cited higher operating expenses across R&D, sales and marketing, and G&A, and said cash fell to $29.4 million from $45.9 million at year-end because of $15 million in operating burn and $2 million in taxes. He said operational cash burn should decrease in the second half as IRRAS integration is completed.

Analysts focused on the strategic pivot, especially whether ClearPoint has enough clinical support capacity to avoid becoming a bottleneck if multiple therapies launch. Management said it already has more than 30, possibly 40, trained clinical specialists, is hiring globally, and believes the bigger decision is to shift resources away from traditional sales roles and toward white-glove clinical support. Questions on 2027 growth and the CAL facility led management to say 2027 growth could be high teens to about 20%, with upside from CAL ramp and possible commercial approvals, and that the first GLP statement of work is in the multi-million-dollar range. On commercial pricing and co-labeling, management said it is actively negotiating ASPs and supply agreements with partners and sees potential for higher commercial pricing, redundancy arrangements, and in some cases royalties.